LGSOC Webinar with Dr Amanda Fader
Dr Amanda Fader is a gynaecological oncologist at Johns Hopkins and the Principal Investigator of theNRG-GY019 clinical trial that could change treatment recommendations for women newly diagnosed with LGSOC Dr Fader presented this informative talk on LGSOC Awareness Day. She generously shared her expertise covering an overview of LGSOC, treatments, clinical trials and new developments […]
Low-Grade Serous Ovarian Cancer Awareness Day September 9, 2025
Low-Grade Serous Ovarian Cancer (LGSOC) is a rare and often overlooked form of ovarian cancer. LGSOC Awareness Day on September 9th shines a spotlight on this uncommon cancer, helping to amplify the voices of those affected and promote life-saving education and research. Because LGSOC receives significantly less funding than other cancer types, raising awareness and […]
Over $400,000 awarded for LGSOC research in the United States
Our United States Research Partner, STAAR Low-Grade Serous Ovarian Cancer, has announced three research grants for low-grade serous ovarian cancer (LGSOC) totalling over $400,000, carefully selected to drive progress in areas where patients need it most. Grant one: A High-Throughput Screening Program to Discover Combinatorial Treatments Targeting Low-Grade Serous Ovarian Cancer Dr Hilary Kenny from […]
Amy MacRae Award for Memoir: 2025 Submissions Open
The Amy Award celebrates exceptional work of memoir writing. The International Amy MacRae Award for Memoir award was created in memory of talented writer, Amy McRae, and aims to improve the lives of women living with ovarian cancer. Amy died at age 35 from low-grade serous ovarian cancer (LGSOC). Entries are open 16 April – […]
FDA to review application for new LGSOC treatment, for those with KRAS mutations under accelerated approval pathway
The FDA has accepted an application for review of avutometinib and defactinib in recurrent low-grade serous ovarian cancer (LGSOC) with KRAS mutations. The application was made under the FDA accelerated approval pathway which allows an application to be considered and conditionally approved before all clinical trials are completed. There currently are no FDA-approved treatments specifically for LGSOC. […]
Kiltwalk 2025
Kiltwalk website Join the Kiltwalk in Glasgow, Aberdeen, Dundee, or Edinburgh and show your support for women with low-grade serous ovarian cancer. Whether you choose the Mighty Stride, Big Stroll, or Wee Wander, every step makes a meaningful impact. Event dates: Glasgow: Saturday, April 26 (New Big Stroll) & Sunday, April 27 Aberdeen: Sunday, June […]
Hope and Progress: Fundraisers and Researchers Collaborate at the Institute of Genetics and Cancer, Edinburgh University
Professor Gourley and his dedicated team of doctors and researchers recently hosted an event to express their gratitude for the ongoing support of their research to advance low-grade serous ovarian cancer (LGSOC). Attendees included individuals with LGSOC and their families, who have contributed to fundraising efforts through the Low-Grade Serous Ovarian Cancer Initiative. Alex Coppock-Bunce […]
LGSOC Webinar With Dr Gershenson
World-renowned low-grade serous ovarian cancer expert Dr David Gershenson, Professor of Gynaecological Oncology and former Department Chair at the University of Texas MD Anderson Cancer Center, delivers an exceptional webinar. In this insightful session, Dr. Gershenson covers key topics related to LGSOC, including diagnosis, current treatment options, and the latest research advancements. https://youtu.be/OmuXjXT6uKk
A Message from Our Founder, Jane Ludemann: We’ve Changed Our Name!
Cure Our Ovarian Cancer is now the Low-Grade Serous Ovarian Cancer Initiative! It’s hard to believe that nearly seven years have passed since I founded Cure Our Ovarian Cancer – the first organisation in the world dedicated to low-grade serous ovarian cancer (LGSOC). My journey began when I was diagnosed with LGSOC at 32 years […]
Study highlights the benefit of surgery in low-grade serous ovarian cancer
In this article, Dr Robb Hollis, of the University of Edinburgh, discusses the findings of his recent research examining the benefits of surgery in ovarian cancers including low-grade serous. There are multiple different types of ovarian cancer, each with their own unique underlying biology (such as gene mutations) and clinical behaviour (aggressiveness and treatment responsiveness). […]